Revvity stock hits new 52-week high as gains extend
Revvity Inc. (RVTY) stock has reached a new 52-week high of $122.26, driven by a 24% year-to-date gain and a 19% advance over the last six months. The company, valued at $13.52 billion, specializes in diagnostic tests and life science research tools. Despite analysts' average price target of $108.36 and some models indicating slight overvaluation, the stock continues its upward momentum, exceeding previous expectations.
Revvity stock hits 52-week high at 122.26 USD
Revvity Inc.'s stock reached a new 52-week high of $122.26, reflecting strong market performance with a 24% year-to-date return. Despite this, InvestingPro analysis suggests the stock is overvalued with a P/E ratio of 57. The company recently surpassed second-quarter earnings and revenue expectations, driven by organic growth and AI demand, though premarket trading showed investor concerns about the sustainability of these results.
Revvity stock hits 52-week high at 122.26 USD By Investing.com
Revvity Inc.'s stock has reached a new 52-week high of $122.26, demonstrating strong market performance with significant year-to-date and six-month gains. Despite an InvestingPro analysis suggesting the stock is overvalued, the company recently exceeded Q2 earnings and revenue expectations, driven by organic growth and increased AI-related demand. However, the stock saw a premarket decline, indicating some investor apprehension.
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain?
AbCellera Biologics (ABCL) recently announced successful Phase 2 trial results for its investigational antibody ABCL635, leading to a significant surge in its stock price, with 30-day and year-to-date returns of 107.07% and 250.15% respectively. Despite this, analysts still view the stock as undervalued, with a consensus price target of $14.62 against its last close of $12.01, suggesting potential for further growth but also highlighting risks associated with later trial stages and high R&D costs. Investors are encouraged to review the details and risk factors as market sentiment can shift rapidly.
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Revvity Inc. (RVTY) stock rose by 5.01% on Wednesday, closing at $119.45, breaking a four-day losing streak. Despite this gain, the stock underperformed compared to the broader market, as both the S&P 500 and Dow Jones Industrial Average also saw gains on the same day.
Revvity stock edges lower as SuperFlex launch and Q2 earnings shape valuation debate
Revvity stock saw a slight dip after launching its SuperFlex prenatal screening system, even as the company reported solid Q2 2026 earnings. The SuperFlex system is a compact, CE-IVDR certified immunoassay instrument designed for rapid, high-quality prenatal screening for lower-volume workflows, particularly targeting preeclampsia. Despite the recent decline, Revvity's shares have shown significant growth over the past year, and analysts suggest the stock is modestly undervalued, supported by its stable earnings and product pipeline.
Revvity (NYSE: RVTY) executive gifts 27,785 shares to trust
Joel S. Goldberg, an officer at Revvity (NYSE: RVTY), reported gifting 27,785 shares of common stock from his direct holdings to the Goldberg Irrevocable 2021 Trust. This transaction reduced his direct holdings to 13,729 shares, while the trust, established for his children's benefit, now indirectly holds 91,494 shares. Goldberg disclaims beneficial ownership of the trust's shares except for any pecuniary interest.
Revvity (NYSE:RVTY) Gains Attention After SuperFlex Launch
Revvity (NYSE:RVTY) is attracting attention following the launch of its SuperFlex prenatal screening system, which expands its diagnostics portfolio and targets laboratories with lower testing volumes. The company's strategy focuses on higher-value products, recurring consumables, software-enabled solutions, and operational efficiency to drive margin strength. While these improvements are positive, valuation remains a key market consideration, and the company's future market direction will depend on whether operational gains can support current market expectations amidst potential funding risks in healthcare and academic research.
Insteel Industries CFO Scot R. Jafroodi Vests 2,017 RSUs, Withholds 526 Shares for Taxes
Insteel Industries CFO Scot R. Jafroodi vested 2,017 restricted stock units on August 14, 2026, and subsequently had 526 shares withheld for tax obligations at $32.62 per share. Following these transactions, Jafroodi's direct ownership in the company stands at 49,731 common shares. The vesting event cleared his RSU balance, as detailed in the SEC Form 4 filing.
Revvity Inc. stock underperforms Tuesday when compared to competitors
Revvity Inc. (RVTY) stock fell 2.08% to $113.75 on Tuesday, marking its fourth consecutive day of losses. This underperformance occurred during a generally negative trading session, with the S&P 500 Index (SPX) dropping 0.69% and the Dow Jones Industrial Average (DJIA) falling 0.22%.
Revvity (RVTY) Could Be 4% Undervalued After SuperFlex Launch And Q2 Update
Revvity (RVTY) has launched its SuperFlex prenatal screening system and released its second-quarter earnings. Despite recent strong stock momentum, with a 90-day return of 21.17% and a 1-year return of 29.88%, the company is considered modestly undervalued by analysts, with a fair value of $121.07 compared to its current price of $116.17. However, its high P/E ratio of 54.6x compared to peers suggests potential valuation risk.
Revvity (RVTY) Could Be 4% Undervalued After SuperFlex Launch And Q2 Update
Revvity (RVTY) has launched its SuperFlex prenatal screening system and released its Q2 earnings, showing strong recent stock momentum. While a valuation narrative suggests the stock is about 4% undervalued at $121.07 compared to its last close, its current P/E ratio of 54.6x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to review the company's fundamentals and risks carefully.
Iridex (NASDAQ:IRIX): Why Is Ophthalmic Systems And Procedure Activity in Focus Today?
Iridex (NASDAQ:IRIX) is scheduled for a financial update today, bringing its ophthalmic systems and procedure activity into focus. Investors will be looking for concrete links between demand, execution, and financial stewardship, particularly how systems, procedures, consumables, and distribution are performing. The article emphasizes that a clear update can demonstrate if recent initiatives are creating a more durable business pattern.
Revvity CEO Prahlad Singh Transfers Over 67,000 Shares to Family Trusts in Gift Transactions
Revvity CEO Prahlad R. Singh transferred over 67,000 shares of the company's common stock to two irrevocable family trusts through gift transactions dated August 13, 2026. These transfers, made at no cost, reduced Singh's direct holdings to 46,026 shares and involved disclaimers of beneficial ownership for the gifted shares. The trusts include the Singh Family Trust of 2021 for his children and the newly created Singh Marital Trust of 2026, managed by Singh and his spouse.
Revvity (NYSE: RVTY) CEO shifts stock into family trusts at $0
Revvity (NYSE: RVTY) CEO Prahlad R. Singh transferred 134,572 shares of common stock into family trusts on August 13, 2026, with the transactions reported at $0.00 per share. These bona fide gifts included 7,636 shares to an irrevocable trust for his children and 59,650 shares to the Singh Marital Trust of 2026. Following these transfers, Singh disclaims beneficial ownership of the gifted securities except for any pecuniary interest.
Revvity (NYSE:RVTY) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen has downgraded Revvity (NYSE:RVTY) from a "buy" to a "hold" rating, aligning with the broader analyst consensus of twelve hold ratings and three buy ratings, with a consensus target price of $108.36. Despite the downgrade, Revvity recently exceeded quarterly earnings expectations with an EPS of $1.41 and revenue of $729.69 million, though revenue saw a slight year-over-year decline. The company's stock opened near its 52-week high, and institutional investors hold a significant 86.65% stake.
T. Rowe Price (RVTY) reports 16.4% Revvity stake, 18.3M shares under control
T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 18,269,089 shares of Revvity Inc. common stock, which accounts for 16.4% of the outstanding class. The firm holds sole voting power over 17,089,376 shares and sole dispositive power over all 18,269,089 shares. The disclosure also notes that T. Rowe Price Capital Appreciation Fund, advised by T. Rowe Price Investment Management, holds 11,237,061 shares, representing 10.1% of the class.
T. Rowe Price Associates (RVTY) discloses 5.0% beneficial stake in Revvity
T. Rowe Price Associates has filed an amended Schedule 13G, disclosing a 5.0% beneficial ownership stake in Revvity Inc (RVTY) as of June 30, 2026. This amounts to 5,526,874 shares, with T. Rowe Price Associates holding sole voting power over 5,508,363 shares and sole dispositive power over all 5,526,874 shares. The firm explicitly denied beneficial ownership, stating the filing should not be construed as such.
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip
VolitionRX (VNRX) reported a wider-than-expected loss and lower revenue for Q2 2026, causing shares to slip. Despite the financial miss, the company highlighted progress in reducing operating costs, advancing scientific data, and developing partnerships in sepsis, cancer, and veterinary diagnostics. Management indicated that revenue remains unpredictable and declined to provide full-year 2026 guidance, focusing instead on long-term strategic milestones and licensing agreements.
Revvity (RVTY) Stock Looks Reasonable On Cash Flow Yet Rich On Earnings
Revvity (RVTY) stock has seen a 34.1% decline over the past five years. While a Discounted Cash Flow (DCF) model suggests the shares are undervalued by 23.0% at $153 per share, earnings-based multiples indicate the stock is expensive, trading at a P/E of 55.4x compared to an industry average of 37.3x. The article highlights a mixed valuation picture, with cash flow models suggesting a bargain due to anticipated growth from new products like the SuperFlex prenatal screening system, but earnings multiples pointing to overvaluation.
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
Revvity, Inc. launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed for small to mid-sized laboratories and clinics. This system aims to expand access to prenatal and preeclampsia testing with its ability to process up to 60 tests per hour and deliver results quickly. The launch is expected to strengthen Revvity's position in the reproductive health market and capitalize on the growing demand for preeclampsia screening.
Revvity Inc. (NYSE:RVTY) Given Average Recommendation of "Hold" by Analysts
Revvity Inc. (NYSE:RVTY) has received an average "Hold" recommendation from analysts, with 12 out of 15 rating it a hold and three a buy. Despite exceeding quarterly earnings and revenue expectations, the company's revenue declined 1.3% year over year, and the average 12-month price target of $108.36 is below its current share price of $117.66. Institutional investors hold a significant 86.65% stake in Revvity, which also announced a quarterly dividend.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) stock advanced 1.86% to $117.88 on Wednesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The stock closed just 0.35% shy of its 52-week high of $118.30. This performance occurred on a mixed trading day for the broader market.
Thermo Fisher Scientific Closes Microbiology Unit Sale to Astorg
Thermo Fisher Scientific has completed the sale of its microbiology unit to Astorg. The article briefly mentions this key transaction and lists recent news updates related to Thermo Fisher Scientific, including analyst rating adjustments and other business developments.
Revvity : Quarterly Report for Quarter Ending July 5, 2026 (Form 10-Q)
Revvity, Inc. released its quarterly report for the quarter ending July 5, 2026, detailing a 1% increase in overall revenue to $729.7 million compared to the prior year. This growth was primarily driven by a 5% increase in the Diagnostics segment, while the Life Sciences segment experienced a 2% decrease. The report also highlights improved gross margins due to tariff refunds and product mix shift, alongside a decrease in operating margins attributed to restructuring charges and digital investments.
Revvity (RVTY) grows Q2 revenue, boosts cash and plans China diagnostics exit
Revvity (RVTY) reported a 1% increase in Q2 2026 revenue to $729.7 million, with Diagnostics growth offsetting a decline in Life Sciences. The company's gross margin improved to 57.1%, and operating cash flow from continuing operations reached $317.8 million for the first half of 2026. Revvity also announced plans to divest its China Immunodiagnostics business, which accounted for approximately 6% of its 2025 revenue.
The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
Revvity's Q2 earnings call revealed year-over-year growth in revenue and adjusted EPS, though the market reacted negatively. Management highlighted strength in Diagnostics and increasing demand for AI-driven tools, leading to an elevated instrument backlog. Analysts focused on the implications of this backlog, the impact of AI customer orders, reagent growth, and the sustainability of newborn screening growth.
Revvity (RVTY) Lifted Its Outlook, Is The Stock Fully Priced?
Revvity (RVTY) recently released its second-quarter 2026 results and declared a dividend, leading to an improved outlook. The stock has seen a 16.84% return over 90 days and 35.60% over one year, yet its 5-year return is down 36.40%. While a "most popular narrative" suggests it's 4.2% undervalued with a fair value of $121.07, its current P/E ratio of 54.5x is above the industry average of 37x, hinting at a potentially rich valuation.
The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
Revvity's Q2 earnings showed revenue and non-GAAP EPS growth, but the market reacted negatively due to segment dynamics and external factors. Management highlighted strength in Diagnostics and increasing demand for AI-driven science tools, resulting in an elevated instrument backlog. The article details the top five analyst questions concerning the instrument backlog, AI customer orders, reagent growth, high-content analysis demand, and the durability of newborn screening growth.
Revvity (RVTY) Lifted Its Outlook, Is The Stock Fully Priced?
Revvity (RVTY) recently released its Q2 2026 results and declared a dividend, leading to a lifted outlook. The stock has seen positive short-term momentum, but its valuation is split, with a fair value estimate suggesting it's undervalued at $121.07, while its P/E ratio of 54.5x is above the industry average, indicating a rich price.
Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains
Revvity Inc. (RVTY) stock rose by 1.19% on Monday, closing at $116.02, marking its second consecutive day of gains. Despite this individual gain, the stock underperformed compared to the broader market, as the S&P 500 Index (SPX) fell 0.06% and the Dow Jones Industrial Average (DJIA) fell 0.11% on the same day.
Revvity Launches SuperFlex Prenatal Screening System for Preeclampsia
Revvity has introduced the SuperFlex prenatal screening system, a compact immunoassay instrument designed for small to mid-sized laboratories and clinics to offer preeclampsia testing and biochemical screening. This CE-IVDR certified system aims to lower financial and operational barriers to in-house prenatal screening, providing access to potentially life-saving testing for more women. The SuperFlex system is initially available in markets accepting CE-marked instruments, with expansion into the Asia-Pacific region planned for late 2026.
Revvity, Inc. (RVTY) Stock Forecasts
Morningstar analyst Julie Utterback published a report on Revvity, Inc. (RVTY), a global life sciences and diagnostics company. The report, titled "Revvity Earnings: Strong but Dressed-Up Quarter Boosts 2026 Outlook," was released on August 4, 2026. Revvity operates in life sciences and signals software segments, and the report is exclusively available through Yahoo Finance Silver.
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
Revvity has launched the SuperFlex prenatal screening system, a compact and affordable immunoassay instrument designed to make preeclampsia testing more accessible to small to mid-sized labs and clinics. This system aims to overcome financial and operational barriers that previously limited such testing to larger, centralized laboratories, thereby expanding access to potentially life-saving screening for pregnant women. The platform is CE-IVDR certified and offers operational simplicity, flexible throughput, and a test menu for both first- and second-trimester biochemical prenatal screening.
Bank of America Corp DE Increases Stake in Revvity Inc. $RVTY
Bank of America Corp DE increased its stake in Revvity Inc. by 14.7% in the first quarter, acquiring 112,928 additional shares, bringing its total to 880,503 shares valued at $77.1 million. Revvity reported strong quarterly earnings of $1.41 per share, surpassing estimates, though revenue saw a slight year-over-year decline. The company also declared a quarterly dividend of $0.07 per share, and analysts currently hold a consensus "Hold" rating with an average price target of $108.36.
Will Raised 2026 Revenue Guidance and Diagnostics Strength Change Revvity's (RVTY) Narrative
Revvity, Inc. recently reported strong Q2 2026 results, including increased revenue guidance and robust Diagnostics performance, leading to a reaffirmed quarterly dividend. Management attributes this positive outlook to improved pharma and biotech demand and a strategic exit from its China immunodiagnostics business. This shift aims to focus on higher-margin areas, potentially reshaping the investment narrative around steady growth in Diagnostics and software, despite ongoing regulatory risks.
Revvity Q2 Earnings Call Highlights
Revvity (RVTY) reported strong second-quarter results, exceeding expectations and raising its full-year outlook due to robust diagnostics performance and increasing demand from pharmaceutical and biotech sectors, particularly in AI-enabled drug discovery. The company saw pro forma organic revenue growth of 3% and adjusted earnings per share of $1.41. Revvity’s CFO highlighted significant contributions from the Diagnostics segment and improving order activity in Life Sciences, especially for AI-driven drug discovery tools.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, key financial statistics, historical performance, and analyst ratings. It details the company's operations in animal diagnostics, water quality, and veterinary software, and compares its performance to benchmarks like the S&P 500 and similar companies. The content is current as of August 7, 2026, with an analyst rating update on August 5, 2026.
Will Raised 2026 Revenue Guidance and Diagnostics Strength Change Revvity's (RVTY) Narrative
Revvity, Inc. (RVTY) reported strong Q2 2026 results, raising its full-year 2026 pro forma revenue guidance to US$2.83 billion to US$2.86 billion, driven by improving pharma/biotech demand and strong Diagnostics performance. The company is focusing on higher-margin areas by exiting its China immunodiagnostics business. This update supports Revvity's investment narrative of building a higher-margin mix around Diagnostics and software, despite ongoing policy and pricing pressures.
Will Raised 2026 Revenue Guidance and Diagnostics Strength Change Revvity's (RVTY) Narrative
Revvity, Inc. (RVTY) reported strong Q2 2026 results with increased revenue guidance for the full year, driven by improving pharma/biotech demand and robust Diagnostics performance. The company is strategically exiting its China immunodiagnostics business to focus on higher-margin areas, aiming for a narrative built around Diagnostics and software growth. While analysts are optimistic, regulatory risks in healthcare and China remain a key consideration for investors.
ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Erasca, Inc. (ERAS) on behalf of investors who purchased stock between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, which was later accused of infringing on a Revolution Medicines patent and misappropriating trade secrets, leading to a significant drop in Erasca's stock price. Investors have until August 10, 2026, to apply to be lead plaintiff.
Revvity, Inc. (0KHE) Q3 2022 Earnings Report - Results, Call & Slides
Revvity, Inc. (0KHE) has released its Q3 2022 earnings report, showing an actual EPS of $1.51, which beat the consensus EPS of $1.44. However, the company missed revenue expectations, reporting $711.80 million against an expected $1.02 billion, a 38.99% year-over-year decrease. The earnings call took place on November 8, 2022, and the next estimated earnings date for Revvity is November 2, 2026.
Will Raised 2026 Revenue Guidance and Diagnostics Strength Change Revvity's (RVTY) Narrative
Revvity, Inc. reported strong Q2 2026 results, including higher sales and net income, reaffirmed its dividend, and raised its full-year 2026 revenue guidance to US$2.83 billion to US$2.86 billion. This positive outlook is driven by improving demand in pharma and biotech, robust Diagnostics performance, and strategic exits from lower-margin businesses. The article suggests this momentum could reshape Revvity's investment narrative, emphasizing its focus on higher-margin Diagnostics and software while navigating market risks.
AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate
AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being used to fund its antibody pipeline. While partner deals provide non-dilutive funding, concerns remain about the gap between low recurring revenue and high R&D spending, posing a financing and dilution risk.
REVVITY, INC. : STIFEL RAISES TARGET PRICE TO $110 FROM $100
Stifel has raised its target price for Revvity, Inc. from $100 to $110. This adjustment in the target price suggests a more optimistic outlook by Stifel on the company's future stock performance.
Revvity Inc. Lifts Guidance After Strong Earnings
Revvity Inc. reported strong Q2 earnings, exceeding revenue and EPS guidance, leading to raised full-year targets. The Diagnostics segment and high-content screening orders were key growth drivers, while software revenue experienced volatility. The company also demonstrated strong cash flow, deleveraging progress, and an accelerated integration of ACD/Labs, despite some one-time benefits influencing the Q2 results.
Why Revvity (RVTY) Stock Is Up Today
Shares of Revvity (NYSE:RVTY) jumped 3.1% after the life sciences company reported strong second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year guidance. The company announced adjusted EPS of $1.41 on revenue of $729.68 million, driven by 11% organic growth in its Diagnostics segment. Analysts at Stifel and Bernstein increased their price targets for RVTY following the positive report.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) stock rose 3.26% to $115.02 on Wednesday, outperforming the broader market's mixed performance. The company's shares closed 2.77% below their 52-week high of $118.30. This positive movement occurred despite the Dow Jones Industrial Average rising and the S&P 500 Index falling on the same trading day.
Stifel raises Revvity stock price target to $110 on earnings beat
Stifel increased its price target for Revvity Inc (NYSE:RVTY) shares to $110 from $100, maintaining a Hold rating after the company reported strong Q2 2026 earnings that exceeded expectations. The beat was partly due to tariff refunds and tax savings, but also organic growth in diagnostics and accelerating life science orders. Revvity raised its guidance for organic growth and earnings, planning to reinvest the remaining profit into supply chain and R&D.
Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Equalweight Rating
Barclays has increased its price target for Revvity (RVTY) shares to $115 from $105, while maintaining an Equalweight rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also briefly mentions other analysts like Bernstein, Evercore ISI, and Jefferies who have also recently revised their price targets for Revvity.
